Literature DB >> 27934636

Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor.

Y Amy Siu1, W George Lai1.   

Abstract

Accurately assessing the contribution of cytochrome P450 (P450) isoforms to overall metabolic clearance is important for prediction of clinical drug-drug interactions (DDIs). The relative activity factor (RAF) approach in P450 reaction phenotyping assumes that the interaction between P450-selective probes and testing systems is the same as the interaction of drug candidate with those systems. To test this assumption, an intersystem clearance ratio (ICR) was created to evaluate the difference in values between RAF-scaled intrinsic clearance (CLint) and measured CLint in human liver microsomes (HLMs). The RAF value for CYP3A4 or CYP2C9 derived from a particular P450-selective probe reaction was applied to calculate RAF-scaled CLint for other probe reactions of the same P450 isoform in a crossover manner and compared with the measured HLM CLint When RAF derived from midazolam or nifedipine was used for CYP3A4, the ICR for testosterone 6β-hydroxylation was 31 and 25, respectively, suggesting significantly diverse interactions of CYP3A4 probes with the testing systems. Such ICR differences were less profound among probes for CYP2C9. In addition, these RAF values were applied to losartan and meloxicam, whose metabolism is mostly CYP2C9 mediated. Only using the RAF derived from testosterone for CYP3A4 produced the expected CYP2C9 contribution of 72%-87% and 47%-69% for metabolism of losartan and meloxicam, respectively. RAF derived from other CYP3A4 probes would have attributed predominantly to CYP3A4 and led to incorrect prediction of DDIs. Our study demonstrates a significant impact of probe substrate selection on P450 phenotyping using the RAF approach, and the ICR may provide a potential solution.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27934636     DOI: 10.1124/dmd.116.073510

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.

Authors:  Bo Lindmark; Anna Lundahl; Kajsa P Kanebratt; Tommy B Andersson; Emre M Isin
Journal:  Br J Pharmacol       Date:  2018-04-19       Impact factor: 8.739

2.  Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation.

Authors:  Dustyn A Barnette; Mary A Davis; Noah Flynn; Anirudh S Pidugu; S Joshua Swamidass; Grover P Miller
Journal:  Biochem Pharmacol       Date:  2019-10-09       Impact factor: 5.858

3.  Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study.

Authors:  Michael T Eadon; Judith Maddatu; Sharon M Moe; Arjun D Sinha; Ricardo Melo Ferreira; Brent W Miller; S Jawad Sher; Jing Su; Victoria M Pratt; Arlene B Chapman; Todd C Skaar; Ranjani N Moorthi
Journal:  Kidney360       Date:  2022-02-24

4.  In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.

Authors:  Heather Zhang; Ying C Ou; Dan Su; Fan Wang; Lai Wang; Srikumar Sahasranaman; Zhiyu Tang
Journal:  Pharmacol Res Perspect       Date:  2021-12

5.  Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism.

Authors:  Josefine Schulz; Antonia Thomas; Ayatallah Saleh; Gerd Mikus; Charlotte Kloft; Robin Michelet
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.